Common epitopes on S-antigen (arrestin), a potent autoantigen inducing experimental autoimmune uveoretinitis (EAU), and on human tumor necrosis factor alpha (hTNFa) are revealed with monoclonal antibodies (mAb) to S-antigen, which inhibit EAU induction. The minimal common sequence for mAb recognition is GVxLxD in the S-antigenlhTNFa amino acid (aa) sequences. Peptides containing this sequence motif exhibit monocyte activating capacity analogous to the autocrine stimulatory capacity of hTNFa itself. In S-antigen this activity is located at epitope S2 (aa residues 40 to 50), corresponding to the peptide PVDGVVLVDPE (peptide S2). In hTNFa the monocyte activating capacity correlates to aa residue 31 to 53, corresponding to the peptide RRANALLANGVELRDNQLVVPSE (peptide RRAN). Peptide S2 but not peptide RRAN is competing for mAbs S6H8 and S2D2 binding to S-antigen. Anti-idiotypic antibodies to S2D2 compete with peptide S2 but not peptide RRAN for binding to mAbs S2D2 and S6H8. In human retinal S-antigen epitope S2 is localized at the aa residues 44-54 and is cleaved in the human peptide 4 (aa 31-50). Competition experiments with peptide 4 (aa 31-50) and peptide 5 (aa 41-60) indicate that the C-terminal aa residues VDPD in the epitope S2 play an important role for internal image recognition of the anti-idiotypic antibodies. Peptide S2 and peptide RRAN define common functional structures in the autoantigen and hTNFa molecules. The data suggest regulatory functions of the peptides in cytokine expression, network regulation and in autoimmunity.
INTRODUCTION
Experimental autoimmune uveoretinitis (EAU) is a model of ocular autoimmune disease produced in laboratory animals by immunization with retinal S-antigen (S-Ag) (1,2). S-Ag, also named arrestin or 48K protein, is a 404 aa residue soluble protein of retinal photoreceptors involved in regulation of visual transduction (3). Experiments by Y. revealed that a particular region of S-Ag is involved in immunoregulation of S-Ag-induced EAU. Some mAbs to S-Ag (S2D2, S6H8 and S7D6) prevent EAU when they are injected to rats at the time of immunization with S-Ag (4). Preimmunization with these mAbs also inhibits EAU induction (5), as do preimmunization with purified rat anti-idiotypic antibodies raised against mAb S2D2 (6). Lewis rats, a strain highly susceptible to S-Aginduced EAU, have a delayed antibody response against the epitope recognized by mAb S2D2, compared with the refractory BN strain (7). The epitope recognized by these mAbs is phylogenetically conserved in the retinal S-Ag of vertebrates and invertebrates (8) and is present in S-Ag-like proteins from several non ocular cells (9,lO) including brain 8-
We localized the epitope(s) (S2) recognized by mAbs S2D2, S6H8, S7D6, S8D8 and S8D1 in the N-terminus of the S-Ag sequence. Epitope S2 displays a common sequence motif with TNFa. In vitro experiments using synthetic peptides from bovine S-Ag (peptide S2) and from hTNFa (peptide RRAN) showed that these peptides stimulate TNFa mRNA expression in human monocytes (12), an effect analogous to the autocrine stimulatory capacity of the hTNFa molecule itself (13) , and TNFa secretion. The characteristics of these epitopes were analysed in aa residue exchange experiments (1 4).
common epitopes and present new data concerning competition of anti-idiotype S2D2 antibodies and peptides with S-Ag for binding to mAb S2D2. Materials and methods used are described in references 12 and 14.
We summarize here the properties of the S-AgTTNFa
Received on January 13. 1992; accepted on April 20, 1992 Peptide number peptide number mAb recognition Peptlde number Figure 1 : lmmunoreactivity profile of a) 68 heptapeptides overlapping by six aa residues from bovine retinal S-Ag (N-terminal residues 1-74) and b) 75 heptapeptides overlapping by five aa residues from the complete mature hTNFa molecule. The S-AghTNFa common epitopes are revealed with mAb S6H8 (1 pg/ml) and horseradish peroxidase labeled protein A (Bio-Rad).
LOCALIZATION OF CROSSREACTIVE EPITOPES IN
The phylogenetically conserved epitope(s) S2 recognized by mAbs S2D2, S6H8, S7D6, S8D8 and S8D1 was mapped to the N-terminal CNBr fragment CB 74 of bovine retinal S-Ag by different methods (7) . PEPSCAN analysis allowed to compare the reactivity of 68 synthetic heptapeptides overlapping by six aa residues reproducing this 74 aa N-terminal region. Epitope S2 was localized at the aa residues 40 to 50 (PVDGVVLVDPE, peptide S2) as shown for mAb S6H8 in Figure 1 a. The immunoreactivity profile for the other mAbS was nearly identical as for the mAb S6H8. The boundaries of the epitope appear to be proline in position 40 and glutamic acid in position 50. With the disappearance of proline 40, the immunoreactivity was negligible and reappeared with the next overlapping peptide starting with aspartic acid 42 ( fig. 1 a) . None of the mAbs was interacting with the presently known T-cell stimulating and uveitopathogenic sites which are located in the C-terminal part of S-Ag (CB 123, CB 35, CB 46) (15) (16) (17) (18) (19) (20) (21) , whereas peptide S2 exhibits no uveitopathogenicity (unpublished result, Y. de Kozak). PEPSCAN-analysis of the hTNFa molecule with S-ANTIGEN AND HUMAN TNFa Figure 2 a demonstrates that only peptide S2 and not peptide RRAN impairs binding of mAb S6H8 to S-Ag. The same result was found for S2D2. Purified antiidiotypic antibodies compete also with S2 but not with RRAN for their binding to mAbs S6H8 (Figure 2 b) and S2D2. In this type of experiment we tested four other S-Ag peptides, among which human peptide 4 (aa 31-50) is cleaving epitope S2 (localized at the aa 44-54 of human S-Ag) and peptide 5 (aa 41-60) is containing the complete epitope S2. Peptide 4, which contains only the N-terminal residues PVDGVVL of epitope S2, does not compete with the internal image, whereas peptide 5 exhibits the same competing activity as peptide S2. This indicates that the C-terminal residues VDPD of the human and/or VDPE of the bovine epitope S2 play an essential role in the internal image. The sequence of ANTIBODIES TO S-AG AND POLYCLONAL ANTI- VDPD can be cleaved by acidic hydrolysis between aspartic acid (D) and proline (P). Two control peptides, the uveitopathogenic peptide M (aa residues 303-320) from bovine S-Ag and human peptide 1 (aa residues 1-20), had no effect in the competition experiment. 
CONCLUSIONS AND PERSPECTIVES

Peptide dllution
TNFa in a bioassay. The idiotypic approach developed for epitope S2 will be a useful tool to characterize the cytokine inducing receptor(s).
S-Ag appears to be a member of a larger protein family. The cytokine inducing function of epitope S2, whose aa sequence is identical in p-arrestin (the only analog whose sequence is known at the present time) could be involved in other autoimmune diseases and/or participa!e as cofactor in other pathological processes. The possibility of direct cytokine induction by autoantigens deserves investigation in other models of autoimmune diseases, such as EAU and EAP induced by rhodopsin and IRBP or experimental autoimmune encephalomyelitis (EAE) induced by myelin basic protein. The mAbs which recognize the S-Ag and TNFa cytokine-inducing peptides should be evaluated for their influence on these autoimmune diseases and on other TNFa-mediated experimental diseases.
Presently human peptide RRAN, bovine peptide S2, human peptides 4 and 5 are tested for their effects on EAU induction by S-Ag immunization. The activity of these peptides on EAU induction and their influence on autoimmune network and cytokine network modulation could influence therapeutic approaches in autoimmune disease models. 
+ peptide RRAN (RRANALLANGVELRDNQLVVPSE)
A peptide M (DTNLASSTIIKEGIDKTV). Competing peptides were serially twofold diluted starting with an initial peptide concentration of 1000 molar excess over the coated S-Ag or 10000 molar excess over the coated mAb S6H8.
